ALNY
Alnylam Pharmaceuticals Inc
256.00$
+2.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +28.4% | -8.9% | +58.0% | -21.1% | +52.1% | +42.2% | +6.9% | -2.7% | +8.0% | +10.7% | +17.1% | |
| – | +48.1% | -10.5% | +80.2% | -32.2% | +41.9% | +52.4% | +7.4% | -4.1% | +10.8% | +10.5% | +22.9% | |
| – | +140.6% | +7.0% | +233.3% | -34.9% | +30.2% | -9.2% | +65.1% | +5.7% | -6.2% | +18.9% | +71.5% | |
| – | +55.1% | -12.8% | +80.8% | -36.5% | +41.8% | +22.0% | +29.9% | -10.0% | +11.3% | +10.5% | +7.9% | |
| – | -79.2% | +181.2% | +45.7% | -44.8% | +129.3% | +1,300.6% | -67.0% | +19.8% | +37.7% | +23.6% | +91.8% | |
| – | – | +0.0% | +0.0% | +2,406,799,900.0% | +134.1% | +33.5% | +14.8% | +49.3% | -30.9% | -11.9% | +5.4% | |
| – | +27.9% | +312.0% | +58.8% | +76.3% | +32.6% | +9.4% | +7.9% | +4.3% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | +163.7% | – | – | |
| – | -15.0% | +181.3% | -33.4% | +19.5% | +250.6% | +150.0% | +27.8% | +21.3% | +9.3% | +3.0% | +0.1% | |
| – | -34.9% | +210.1% | +3.0% | +22.5% | +45.2% | +66.0% | +18.9% | +10.4% | +26.0% | +22.6% | +23.6% | |
| – | +34.3% | +70.8% | -4.6% | +473.1% | -56.0% | +33.2% | +10.0% | +3.5% | -1.1% | +0.9% | +8.7% | |
| – | +11.1% | +224.4% | -47.9% | +110.6% | -16.5% | +4.2% | +41.3% | +33.6% | -43.4% | +59.3% | +30.9% | |
| – | – | – | -80.0% | +0.0% | – | – | +253.3% | +50.5% | +0.4% | +0.4% | -1.6% | |
| – | +35.1% | -27.2% | +92.0% | -26.3% | +10.5% | -29.4% | -42.1% | -126.9% | – | – | +1,076.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +13.1% | +1.9% | +5.8% | +11.1% | +8.6% | +5.2% | +3.0% | +2.7% | +2.6% | +2.2% | +5.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.